论文信息 - Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. - 字舞流文

Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.

I. Burger | G. Rogler | A. Curioni-Fontecedro | D. Franzen | M. van den Broek | C. Ickenberg | Gerhard Rogler | Irene A. Burger | A. Curioni-Fontecedro | Daniel Franzen | M. F. V. D. Broek

[1] Kaoru Tanaka,et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. , 2016, Lung cancer.

[2] S. Khozin,et al. Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial. , 2016 .

[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4] M. Buck,et al. T cell metabolism drives immunity , 2015, The Journal of experimental medicine.

[5] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.